Loss of HIV-infected patients on potent antiretroviral therapy programs in Togo: risk factors and the fate of these patients

Pan Afr Med J. 2013 May 26:15:35. doi: 10.11604/pamj.2013.15.35.2198. eCollection 2013.

Abstract

Introduction: National programs are facing challenges of loss to follow-up of people living with HIV/AIDS (PLWHA) on antiretroviral therapy (ART). We sought to identify risk factors associated with early loss to follow-up among HIV-infected patients on ART in Togo and the outcome of such patients.

Methods: This was a retrospective cross-sectional study using medical records of all patients older than age 15 years enrolled at 28 treatment centers who were on ART programs and who were lost to follow-up from 2008 to 2011.

Results: Of the 16,617 patients on ART, 1,216 (7.3%) were lost to follow-up. Most (94.1%) were infected with HIV-1 and 32.6% were in WHO stage III or IV. The median CD4 count was 118/mm3 (IQR: 58-178 cells/mm3). No telephone number was mentioned in the medical records of 212 patients. Of the 1004 patients whose phone number was listed, 802 patients (79.9%) were not reachable on the recorded number, 114 patients (11.4%) were alive and 88 patients (8.8%) had died. In multivariate analysis, factors associated with loss to follow-up during the first 6 months of ART were: age below 35 years (OR = 1.6; 95%CI: 1.2-2.2), female sex (OR = 1.8; 95%CI: 1.3-2.5), WHO stage III or IV (OR = 1.7; 95%CI: 1.3-2.2), existence of an opportunistic infection (OR = 2.3; 95%CI: 1.5-3.1), and follow-up in a public centre (OR = 1.9; 95%CI: 1.2-3.3).

Conclusion: This study identified several factors associated with lost to follow-up during the first 6 months of ART, and confirmed high mortality among these patients. The National AIDS Program should strengthen medical support of PLWHA in Togo including active case follow-up.

Keywords: Africa; HIV; Togo; human immunodeficiency virus; lost to follow-up; people living with HIV.

Publication types

  • Multicenter Study

MeSH terms

  • AIDS-Related Opportunistic Infections / epidemiology*
  • Adult
  • Age Factors
  • Anti-HIV Agents / therapeutic use
  • CD4 Lymphocyte Count
  • Cross-Sectional Studies
  • Female
  • Follow-Up Studies
  • HIV Infections / drug therapy*
  • HIV Infections / epidemiology
  • Humans
  • Lost to Follow-Up*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • National Health Programs / statistics & numerical data*
  • Retrospective Studies
  • Risk Factors
  • Sex Factors
  • Togo / epidemiology

Substances

  • Anti-HIV Agents